Identification of tumor antigens with immunopeptidomics
Kloetzel, P. M. Antigen processing by the proteasome. Nat. Rev. Mol. Cell Biol. 2, 179–187 (2001).
Coulie, P. G. et al. A mutated intron sequence codes for an antigenic peptide known by cytolytic T lymphocytes on a human melanoma. Proc. Natl Acad. Sci. USA 92, 7976–7980 (1995).
Roche, P. A. & Furuta, Okay. The fine details of MHC class II-mediated antigen processing and presentation. Nat. Rev. Immunol. 15, 203–216 (2015).
Yewdell, J. W., Reits, E. & Neefjes, J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 3, 952–961 (2003).
Schumacher, T. N., Scheper, W. & Kvistborg, P. Cancer neoantigens. Annu. Rev. Immunol. 37, 173–200 (2019).
Bianchi, V., Harari, A. & Coukos, G. Neoantigen-deliver adoptive cell therapies for most cancers: making T-cell merchandise more personal. Entrance. Immunol. 11, 1215 (2020).
Curran, M. A. & Glisson, B. S. Novel hope for therapeutic most cancers vaccines within the abilities of immune checkpoint modulation. Annu. Rev. Med. 70, 409–424 (2019).
Haen, S. P., Löffler, M. W., Rammensee, H.-G. & Brossart, P. Towards novel horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat. Rev. Clin. Oncol. 17, 595–610 (2020).
Kruger, S. et al. Advances in most cancers immunotherapy 2019: most trendy trends. J. Exp. Clin. Cancer Res. 38, 268 (2019).
Christofi, T., Baritaki, S., Falzone, L., Libra, M. & Zaravinos, A. Present views in most cancers immunotherapy. Cancers (Basel) 11, 1472 (2019).
Laumont, C. M. et al. Global proteogenomic analysis of human MHC class I-linked peptides derived from non-canonical reading frames. Nat. Commun. 7, 10238 (2016).
Sebestyen, E. et al. Colossal-scale analysis of genome and transcriptome alterations in more than one tumors unveils novel most cancers-linked splicing networks. Genome Res. 26, 732–744 (2016).
Zhao, Q. et al. Proteogenomics uncovers a huge repertoire of shared tumor-deliver antigens in ovarian most cancers. Cancer Immunol. Res. 8, 544–555 (2020).
Ouspenskaia, T. et al. Hundreds of novel unannotated proteins develop the MHC I immunopeptidome in most cancers. Preprint at bioRxiv https://doi.org/10.1101/2020.02.12.945840 (2020).
Chen, J. et al. Pervasive purposeful translation of noncanonical human originate reading frames. Science 367, 1140–1146 (2020).
Ilyas, S. & Yang, J. C. Panorama of tumor antigens in T cell immunotherapy. J. Immunol. 195, 5117–5122 (2015).
Caballero, O. L. & Chen, Y. T. Cancer/testis (CT) antigens: doable targets for immunotherapy. Cancer Sci. 100, 2014–2021 (2009).
Tio, D. et al. Expression of most cancers/testis antigens in cutaneous melanoma: a systematic review. Melanoma Res. 29, 349–357 (2019).
Schooten, E., Di Maggio, A., van Bergen En Henegouwen, P. M. P. & Kijanka, M. M. MAGE-A antigens as targets for most cancers immunotherapy. Cancer Care for. Rev. 67, 54–62 (2018).
D’Angelo, S. P. et al. Antitumor activity linked with extended persistence of adoptively transferred NY-ESO-1 c259T cells in synovial. Sarcoma 8, 944–957 (2018).
Rapoport, A. P. et al. NY-ESO-1–deliver TCR–engineered T cells mediate sustained antigen-deliver antitumor results in myeloma. Nat. Med. 21, 914–921 (2015).
Robbins, P. F. et al. A pilot trial the usage of lymphocytes genetically engineered with an NY-ESO-1–reactive T-cell receptor: lengthy-time length apply-up and correlates with response. Clin. Cancer Res. 21, 1019–1027 (2015).
Laumont, C. M. & Perreault, C. Exploiting non-canonical translation to establish novel targets for T cell-primarily primarily based fully most cancers immunotherapy. Cell. Mol. Lifestyles Sci. 75, 607–621 (2018).
Moreau-Aubry, A. et al. A processed pseudogene codes for a novel antigen known by a CD8+ T cell clone on melanoma. J. Exp. Med. 191, 1617–1623 (2000).
Li, L.-J., Leng, R.-X., Fan, Y.-G., Pan, H.-F. & Ye, D.-Q. Translation of noncoding RNAs: focal point on lncRNAs, pri-miRNAs, and circRNAs. Exp. Cell Res. 361, 1–8 (2017).
Charpentier, M. et al. IRES-dependent translation of the lengthy non coding RNA meloe in melanoma cells produces primarily the most immunogenic MELOE antigens. Oncotarget 7, 59704–59713 (2016).
Roulois, D. et al. DNA-demethylating agents arrangement colorectal most cancers cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961–973 (2015).
Chiappinelli, Okay. B. et al. Inhibiting DNA methylation causes an interferon response in most cancers by dsRNA including endogenous retroviruses. Cell 162, 974–986 (2015).
Attermann, A. S., Bjerregaard, A. M., Saini, S. Okay., Gronbaek, Okay. & Hadrup, S. R. Human endogenous retroviruses and their implication for immunotherapeutics of most cancers. Ann. Oncol. 29, 2183–2191 (2018).
Vigneron, N. et al. An antigenic peptide produced by peptide splicing within the proteasome. Science 304, 587–590 (2004).
Delong, T. et al. Pathogenic CD4 T cells in form 1 diabetes acknowledge epitopes formed by peptide fusion. Science 351, 711–714 (2016).
Yewdell, J. W. & Holly, J. DRiPs salvage molecular. Curr. Opin. Immunol. 64, 130–136 (2020).
Welters, M. J. et al. Induction of tumor-deliver CD4+ and CD8+ T-cell immunity in cervical most cancers patients by a human papillomavirus form 16 E6 and E7 lengthy peptides vaccine. Clin. Cancer Res. 14, 178–187 (2008).
Morgan, R. A. et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene treatment. J. Immunother. 36, 133–151 (2013).
Skipper, J. C. et al. Mass-spectrometric overview of HLA-A*0201-linked peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J. Cancer 82, 669–677 (1999).
Wolf, B. et al. Security and tolerability of adoptive cell treatment in most cancers. Drug Saf. 42, 315–334 (2019).
Purcell, A. W., Ramarathinam, S. H. & Ternette, N. Mass spectrometry-primarily primarily based fully identification of MHC-plod peptides for immunopeptidomics. Nat. Protoc. 14, 1687–1707 (2019).
Caron, E. et al. Prognosis of main histocompatibility complex (MHC) immunopeptidomes the usage of mass spectrometry. Mol. Cell. Proteom. 14, 3105–3117 (2015).
Ritz, D., Kinzi, J., Neri, D. & Fugmann, T. Data-self sustaining acquisition of HLA class I peptidomes on the Q exactive mass spectrometer platform. Proteomics 17, 1700177 (2017).
Gillet, L. C. et al. Centered recordsdata extraction of the MS/MS spectra generated by recordsdata-self sustaining acquisition: a novel thought for fixed and beautiful proteome analysis. Mol. Cell. Proteom. 11, O111.016717 (2012).
Brunner, A.-D. et al. Extremely-excessive sensitivity mass spectrometry quantifies single-cell proteome adjustments upon perturbation. Preprint at bioRxiv 2020.2012.2022.423933 (2020).
Tsou, C. C. et al. DIA-Umpire: total computational framework for recordsdata-self sustaining acquisition proteomics. Nat. Suggestions 12, 258–264 (2015).
Muntel, J. et al. Surpassing 10 000 identified and quantified proteins in a single speed by optimizing unique LC-MS instrumentation and recordsdata analysis device. Mol. Omics 15, 348–360 (2019).
Gessulat, S. et al. Prosit: proteome-wide prediction of peptide tandem mass spectra by deep studying. Nat. Suggestions 16, 509–518 (2019).
Croft, N. P. et al. Kinetics of antigen expression and epitope presentation during virus an infection. PLoS Pathog. 9, e1003129 (2013).
Hassan, C. et al. Merely quantitation of MHC-plod peptides by utility of isotopically labeled peptide MHC complexes. J. Proteom. 109, 240–244 (2014).
Croft, N. P., Purcell, A. W. & Tscharke, D. C. Quantifying epitope presentation the usage of mass spectrometry. Mol. Immunol. 68, 77–80 (2015).
Tan, C. T., Croft, N. P., Dudek, N. L., Williamson, N. A. & Purcell, A. W. Convey quantitation of MHC-plod peptide epitopes by chosen response monitoring. Proteomics 11, 2336–2340 (2011).
Kapp, E. A. et al. An outline, comparison, and beautiful benchmarking of quite loads of publicly accessible MS/MS search algorithms: sensitivity and specificity analysis. Proteomics 5, 3475–3490 (2005).
Kapp, E. & Schutz, F. Overview of tandem mass spectrometry (MS/MS) database search algorithms. Curr. Protoc. Protein Sci. 49, 25.2.1–25.2.19 (2007).
Elias, J. E. & Gygi, S. P. Target-decoy search device for increased self belief in effectively-organized-scale protein identifications by mass spectrometry. Nat. Suggestions 4, 207–214 (2007).
Zhang, J. et al. PEAKS DB: de novo sequencing assisted database seek silent and beautiful peptide identification. Mol. Cell. Proteom. 11, M111.010587 (2012).
Shan, P. & Tran, H. Integrating database search and de novo sequencing for immunopeptidomics with DIA arrangement. J. Biomol. Tech. 30, S23 (2019).
Faridi, P., Purcell, A. W. & Croft, N. P. In immunopeptidomics we desire a sniper pretty than a shotgun. Proteomics 18, e1700464 (2018).
Thompson, A. et al. Tandem mass tags: a novel quantification device for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 75, 1895–1904 (2003).
Pfammatter, S. et al. Extending the comprehensiveness of immunopeptidome analyses the usage of isobaric peptide labeling. Anal. Chem. 92, 9194–9204 (2020).
Ramarathinam, S. H. et al. A peptide-signal amplification device for the detection and validation of neoepitope presentation on most cancers biopsies. Preprint at bioRxiv https://doi.org/10.1101/2020.06.12.145276 (2020).
Stopfer, L. E., Mesfin, J. M., Joughin, B. A., Lauffenburger, D. A. & White, F. M. Multiplexed relative and absolute quantitative immunopeptidomics finds MHC I repertoire alterations prompted by CDK4/6 inhibition. Nat. Commun. 11, 2760 (2020).
d’Atri, V. et al. Adding a novel separation dimension to MS and LC–MS: what’s the utility of ion mobility spectrometry? J. Sep. Sci. 41, 20–67 (2018).
Pfammatter, S. et al. A novel differential ion mobility machine expands the depth of proteome coverage and the sensitivity of multiplex proteomic measurements. Mol. Cell. Proteom. 17, 2051–2067 (2018).
Pfammatter, S., Bonneil, E. & Thibault, P. Enchancment of quantitative measurements in multiplex proteomics the usage of excessive-field uneven waveform spectrometry. J. Proteome Res. 15, 4653–4665 (2016).
Meier, F. et al. Online parallel accumulation-serial fragmentation (PASEF) with a novel trapped ion mobility mass spectrometer. Mol. Cell. Proteom. 17, 2534–2545 (2018).
Nesvizhskii, A. I. Proteogenomics: ideas, applications and computational suggestions. Nat. Suggestions 11, 1114–1125 (2014).
Zhang, M. et al. RNA editing derived epitopes characteristic as most cancers antigens to elicit immune responses. Nat. Commun. 9, 3919 (2018).
Wei, Z. et al. The panorama of tumor fusion neoantigens: a pan-most cancers. Anal. iScience 21, 249–260 (2019).
Löffler, M. W. et al. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. Genome Med. 11, 28 (2019).
Kalaora, S. et al. Exercise of HLA peptidomics and total exome sequencing to establish human immunogenic neo-antigens. Oncotarget 7, 5110–5117 (2016).
Bassani-Sternberg, M., Pletscher-Frankild, S., Jensen, L. J. & Mann, M. Mass spectrometry of human leukocyte antigen class I peptidomes finds stable results of protein abundance and turnover on antigen presentation. Mol. Cell. Proteom. 14, 658–673 (2015).
Khodadoust, M. S. et al. Antigen presentation profiling finds recognition of lymphoma immunoglobulin neoantigens. Nature 543, 723–727 (2017).
Bassani-Sternberg, M. et al. Convey identification of clinically linked neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat. Commun. 7, 13404 (2016).
Binz, P. A. et al. Proteomics Standards Initiative extended FASTA structure. J. Proteome Res. 18, 2686–2692 (2019).
Eng, J. Okay. & Deutsch, E. W. Extending comet for global amino acid variant and put up-translational modification analysis the usage of the PSI extended FASTA structure. Proteomics 72, e1900362 (2020).
Elias, J. E. & Gygi, S. P. Target-decoy search device for mass spectrometry-primarily primarily based fully proteomics. Suggestions Mol. Biol. 604, 55–71 (2010).
Gupta, N., Bandeira, N., Keich, U. & Pevzner, P. A. Target-decoy arrangement and spurious discovery price: when issues will also bound fallacious. J. Am. Soc. Mass Spectrom. 22, 1111–1120 (2011).
Tanner, S. et al. Making improvements to gene annotation the usage of peptide mass spectrometry. Genome Res. 17, 231–239 (2007).
Chong, C. et al. Constructed-in proteogenomic deep sequencing and analytics accurately establish non-canonical peptides in tumor immunopeptidomes. Nat. Commun. 11, 1293 (2020).
Laumont, C. M. et al. Noncoding regions are the principle source of targetable tumor-deliver antigens. Sci. Transl. Med. 10, eaau5516 (2018).
Natty, A. C. et al. Intron retention is a source of neoepitopes in most cancers. Nat. Biotechnol. 36, 1056–1058 (2018).
Attig, J. et al. LTR retroelement expansion of the human most cancers transcriptome and immunopeptidome published by de novo transcript meeting. Genome Res. 29, 1578–1590 (2019).
Kong, Y. et al. Transposable component expression in tumors is expounded with immune infiltration and increased antigenicity. Nat. Commun. 10, 5228 (2019).
Shraibman, B., Melamed Kadosh, D., Barnea, E. & Admon, A. HLA peptides derived from tumor antigens prompted by inhibition of DNA methylation for declare of drug-facilitated immunotherapy. Mol. Cell. Proteom. 15, 3058–3070 (2016).
Calviello, L. et al. Detecting actively translated originate reading frames in ribosome profiling recordsdata. Nat. Suggestions 13, 165–170 (2016).
Erhard, F. et al. Improved Ribo-seq enables identification of cryptic translation occasions. Nat. Suggestions 15, 363–366 (2018).
Ingolia, N. T. et al. Ribosome profiling finds pervasive translation outdoors of annotated protein-coding genes. Cell Accumulate. 8, 1365–1379 (2014).
Slavoff, S. A. et al. Peptidomic discovery of short originate reading physique–encoded peptides in human cells. Nat. Chem. Biol. 9, 59–64 (2013).
Sarkizova, S. et al. A effectively-organized peptidome dataset improves HLA class I epitope prediction across many of the human population. Nat. Biotechnol. 38, 199–209 (2020).
Abelin, J. G. et al. Mass spectrometry profiling of HLA-linked peptidomes in mono-allelic cells enables more beautiful epitope prediction. Immunity 46, 315–326 (2017).
Warren, E. H. et al. An antigen produced by splicing of noncontiguous peptides within the reverse hiss. Science 313, 1444–1447 (2006).
Dalet, A. et al. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc. Natl Acad. Sci. USA 108, E323–E331 (2011).
Michaux, A. et al. A spliced antigenic peptide comprising a single spliced amino acid is produced within the proteasome by reverse splicing of a longer peptide fragment followed by trimming. J. Immunol. 192, 1962–1971 (2014).
Hanada, Okay., Yewdell, J. W. & Yang, J. C. Immune recognition of a human renal most cancers antigen thru put up-translational protein splicing. Nature 427, 252–256 (2004).
Liepe, J. et al. A effectively-organized allotment of HLA class I ligands are proteasome-generated spliced peptides. Science 354, 354–358 (2016).
Faridi, P. et al. A subset of HLA-I peptides are no longer genomically templated: proof for cis- and trans-spliced peptide ligands. Sci. Immunol. 3, eaar3947 (2018).
Liepe, J., Sidney, J., Lorenz, F. Okay. M., Sette, A. & Mishto, M. Mapping the MHC class I–spliced immunopeptidome of most cancers cells. Cancer Immunol. Res. 7, 62–76 (2019).
Paes, W. et al. Contribution of proteasome-catalyzed peptide cis-splicing to viral focusing on by CD8+ T cells in HIV-1 an infection. Proc. Natl Acad. Sci. USA 116, 24748–24759 (2019).
Faridi, P. et al. Spliced peptides and cytokine-driven adjustments within the immunopeptidome of melanoma. Cancer Immunol. Res. 8, 1322–1334 (2020).
Mylonas, R. et al. Estimating the contribution of proteasomal spliced peptides to the HLA-I ligandome. Mol. Cell. Proteom. 17, 2347–2357 (2018).
Rolfs, Z., Solntsev, S. Okay., Shortreed, M. R., Frey, B. L. & Smith, L. M. Global identification of put up-translationally spliced peptides with neo-fusion. J. Proteome Res. 18, 349–358 (2019).
Erhard, F., Dölken, L., Schilling, B. & Schlosser, A. Identification of the cryptic HLA-I immunopeptidome. Cancer Immunol. Res. 8, 1018–1026 (2020).
Vigneron, N., Ferrari, V., Stroobant, V., Abi Habib, J. & Van den Eynde, B. J. Peptide splicing by the proteasome. J. Biol. Chem. 292, 21170–21179 (2017).
Dalet, A., Vigneron, N., Stroobant, V., Hanada, Okay. & Van den Eynde, B. J. Splicing of distant peptide fragments happens within the proteasome by transpeptidation and produces the spliced antigenic peptide derived from fibroblast declare ingredient-5. J. Immunol. 184, 3016–3024 (2010).
Henry, V. J., Bandrowski, A. E., Pepin, A. S., Gonzalez, B. J. & Desfeux, A. OMICtools: an informative directory for multi-omic recordsdata analysis. Database (Oxford) 2014, bau069 (2014).
Afgan, E. et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res. 46, W537–W544 (2018).
Nesvizhskii, A. I. et al. Dynamic spectrum quality overview and iterative computational analysis of shotgun proteomic recordsdata: in opposition to more environment friendly identification of put up-translational adjustments, sequence polymorphisms, and novel peptides. Mol. Cell. Proteom. 5, 652–670 (2006).
Andreatta, M. et al. MS-Rescue: a computational pipeline to amplify the quality and yield of immunopeptidomics experiments. Proteomics 19, e1800357 (2019).
Rolfs, Z., Müller, M., Shortreed, M. R., Smith, L. M. & Bassani-Sternberg, M. Touch upon ‘A subset of HLA-I peptides are no longer genomically templated: proof for cis- and trans-spliced peptide ligands’. Sci. Immunol. 4, eaaw1622 (2019).
McGranahan, N. & Swanton, C. Clonal heterogeneity and tumor evolution: previous, unique, and the lengthy speed. Cell 168, 613–628 (2017).
Marcu, A. et al. The HLA Ligand Atlas. A resource of pure HLA ligands presented on benign tissues. J. Immunother. Cancer 9, e002071 (2019).
Schatton, T. et al. Identification of cells initiating human melanomas. Nature 451, 345–349 (2008).
Lang, D., Mascarenhas, J. B. & Shea, C. R. Melanocytes, melanocyte stem cells, and melanoma stem cells. Clin. Dermatol. 31, 166–178 (2013).
Kassiotis, G. & Stoye, J. P. Immune responses to endogenous retroelements: taking the unsuitable with the correct. Nat. Rev. Immunol. 16, 207–219 (2016).
Rycaj, Okay. et al. Cytotoxicity of human endogenous retrovirus Okay–deliver T cells in opposition to autologous ovarian. Cancer Cells 21, 471–483 (2015).
Saini, S. Okay. et al. Human endogenous retroviruses salvage a reservoir of T cell targets in hematological cancers. Nat. Commun. 11, 5660 (2020).
Mullins, C. S. & Linnebacher, M. Endogenous retrovirus sequences as a novel class of tumor-deliver antigens: an instance of HERV-H env encoding stable CTL epitopes. Cancer Immunol. Immun. 61, 1093–1100 (2012).
Tu, X. et al. Human leukemia antigen-A*0201-restricted epitopes of human endogenous retrovirus W household envelope (HERV-W env) induce stable cytotoxic T lymphocyte responses. Virol. Sin. 32, 280–289 (2017).
Belgnaoui, S. M., Gosden, R. G., Semmes, O. J. & Haoudi, A. Human LINE-1 retrotransposon induces DNA injure and apoptosis in most cancers cells. Cancer Cell Int. 6, 13 (2006).
Scott, E. C. et al. A sizzling L1 retrotransposon evades somatic repression and initiates human colorectal most cancers. Genome Res. 26, 745–755 (2016).
Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).
Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-deliver therapeutic immunity in opposition to most cancers. Nature 547, 222–226 (2017).
Ebrahimi-Nik, H. et al. Mass spectrometry driven exploration finds nuances of neoepitope-driven tumor rejection. JCI Perception 5, e129152 (2019).
Smith, C. C. et al. Different tumour-deliver antigens. Nat. Rev. Cancer 19, 465–478 (2019).
Jackson, R. et al. The interpretation of non-canonical originate reading frames controls mucosal immunity. Nature 564, 434–438 (2018).
Muller, M., Gfeller, D., Coukos, G. & Bassani-Sternberg, M. ‘Hotspots’ of antigen presentation published by human leukocyte antigen ligandomics for neoantigen prioritization. Entrance. Immunol. 8, 1367 (2017).
Schittenhelm, R. B. et al. A total analysis of constitutive naturally processed and presented HLA-C*04: 01 (Cw4)-deliver peptides. Tissue Antigen. 83, 174–179 (2014).
Schuster, H. et al. The immunopeptidomic panorama of ovarian carcinomas. Proc. Natl Acad. Sci. USA 114, E9942–E9951 (2017).
Sarkizova, S. et al. A effectively-organized peptidome dataset improves HLA class I epitope prediction across many of the human population. Nat. Biotechnol. 38, 199–209 (2020).
Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in Share Ib glioblastoma trial. Nature 565, 234–239 (2019).
Shraibman, B. et al. Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. Mol. Cell. Proteom. 17, 2132–2145 (2018).
Ternette, N. et al. Immunopeptidomic profiling of HLA-A2-certain triple harmful breast most cancers identifies doable immunotherapy arrangement antigens. Proteomics 18, 1700465 (2018).